Clinical trial
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
NCT00471510 · Neosil, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00471510 |
|---|---|
| Title | Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss |
| Official title | A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men |
| Lead sponsor | Neosil, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Androgenetic Alopecia |
| Intervention type | Drug |
| Interventions | tetrapeptide aldehyde proteasome inhibitor (NEOSH101) |
| Enrollment | 140 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2008 |
| First posted | May 10, 2007 |
| Last update posted | May 20, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: